PharVision Advisers’s T. Rowe Price TROW Stock Holding History

PharVision Advisers’s Portfolio TROW Stock Details TROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,757	Closed	-$386K	–	1006
2025 Q3	$386K	Buy	+3,757	New	+$395K	0.22%	96

Other funds holding TROW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PharVision Advisers's TROW Position: Q4 2025 in Review

PharVision Advisers sold out of T. Rowe Price (TROW) in Q4 2025, closing a stake of 3,757 shares — an estimated $386K sold.

PharVision Advisers first reported a position in TROW in Q3 2025 and held it in 1 quarter. The position peaked at $386K in Q3 2025. 1,125 funds tracked by Wall St. Rank hold TROW as of Q4 2025.

PharVision Advisers reported no remaining T. Rowe Price position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 3,757 T. Rowe Price shares in Q4 2025, an estimated $386K.
PharVision Advisers first reported a position in T. Rowe Price in Q3 2025 and held it in 1 quarter.
PharVision Advisers's T. Rowe Price position peaked at $386K in Q3 2025.
1,125 funds tracked by Wall St. Rank held T. Rowe Price as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.